Hidradenitis suppurativa is associated with non-alcoholic fatty liver disease: A cross-sectional study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Dokumenter

  • 5846

    Forlagets udgivne version, 307 KB, PDF-dokument

  • Iris González-Villanueva
  • Cristina DE GRACIA
  • Mariana Planells
  • Inés Poveda
  • Pedro Álvarez
  • Luca Schneller-Pavelescu
  • Isabel Betlloch
  • Jemec, Gregor
  • José M. Ramos
  • José C. Pascual

Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of end-stage liver disease. The aim of this controlled cross-sectional study was to as-sess the association between NAFLD and hidradenitis suppurativa. NAFLD was assessed using hepatic ultra-sound. A total of 125 patients with hidradenitis suppu-rativa and 120 patients without hidradenitis suppu-rativa were recruited, matched for age, sex and body mass index (< 25 or ≥ 25 kg/m2), a risk factor related to NAFLD. Both groups presented similar proportions of overweight or obesity (89.6% vs 90%). Patients with hidradenitis suppurativa presented significantly higher prevalence of NAFLD compared with those with non-hidradenitis suppurativa (57.6% vs 31.7%, p < 0.001). Multivariable analysis confirmed independent association between hidradenitis suppurativa and NAFLD (odds ratio 2.79, 95% confidence interval 1.48–5.25; p = 0.001) besides age, body mass index, hypertension and hypertransaminasaemia. Hidrade-nitis suppurativa is significantly associated with the development of NALFD regardless of the presence of classic metabolic risk factors.

OriginalsprogEngelsk
Artikelnummeradv00239
TidsskriftActa Dermato-Venereologica
Vol/bind100
Udgave nummer15
Sider (fra-til)1-5
Antal sider5
ISSN0001-5555
DOI
StatusUdgivet - 2020

Bibliografisk note

Funding Information:
This study has received a grant from the Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation).

Funding Information:
This study has received a grant from the Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation). GJ has been an investigator, consultant, and advisory board member for Abbvie and Novartis and has received unrestricted grants from Abbvie, Leo Pharma, and Novartis. In addition, he has been a speaker and investigator for Leo Pharma; a speaker for Galderma; an investigator for Regeneron; and an advisory board member for Janssen-Cilag, Inflarx, MSD, and Pierre-FAbre. JCP has been an advisory board member for Abbvie. IG-V, CDG, MP, IP, PA, LS-P, IB and JMR have no conflicts of interest to declare.

Funding Information:
GJ has been an investigator, consultant, and advisory board member for Abbvie and Novartis and has received unrestricted grants from Abbvie, Leo Pharma, and Novartis. In addition, he has been a speaker and investigator for Leo Pharma; a speaker for Galderma; an investigator for Regeneron; and an advisory board member for Janssen-Cilag, Inflarx, MSD, and Pierre-FAbre. JCP has been an advisory board member for Abbvie. IG-V, CDG, MP, IP, PA, LS-P, IB and JMR have no conflicts of interest to declare.

Publisher Copyright:
© 2020 Acta Dermato-Venereologica.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 271640029